Johnson & Johnson (J&J) may have lost its gamble in Oklahoma in choosing not to settle a public nuisance suit related to its marketing of opioid products, but it's not ready to fold its cards. Read More
By streamlining processes, cutting costs and improving data quality, artificial intelligence (AI) and machine learning can reduce clinical trial spend and speed time to market. The technology is showing up in a number of applications, from guiding recruitment to developing biomarkers to determine who will respond to certain treatments and driving cost efficiencies. Read More
Just as artificial intelligence (AI) becomes an ever-more common part of drug discovery, its potential role in clinical trials is slowly becoming more visible, too. Efforts to improve trial recruitment, efficiency and decision-making are underway at companies of all sizes as organizations look to better the oft-daunting odds of clinical success, industry executives told BioWorld. Read More
LONDON – The industry has set down ethical principles for the use of CRISPR and other gene editing technologies in the development of therapies, for the first time coming out against any application that involves modifying the human germline. Read More
BEIJING – Innovent Biologics Inc., of Suzhou, China, has in-licensed diabetes drug OXM-3 from Eli Lilly and Co. to develop and commercialize it in China. Read More
Cirqle Biomedical, of Copenhagen, said it secured $1.8 million for preclinical development of a non-hormonal contraceptive technology that leverages the natural barrier properties of cervical mucus. It has developed a topically-applied biopolymer that makes cervical mucus impenetrable to sperm cells throughout a woman's cycle. Read More
Zealand Pharma A/S, of Copenhagen, is relocating into new corporate headquarters about 12 kilometers from its current facilities. Relocation is planned to begin in September, with the phased move of laboratories completing by the end of the year. The move will accommodate Zealand's continued workforce growth, which has been steadily increasing to support the number of clinical development programs as well as the longer-term strategic initiative for introducing commercial support, the company said. Read More
LONDON – The EMA's decision to drop Novartis AG's spinal muscular atrophy treatment Zolgensma from its accelerated assessment program looked perfectly understandable in light of the subsequent revelation of potential data manipulation during animal tests of the gene therapy. Read More
